PTPRC and neoplasm: These hybrid cells express both tumor and immune phenotypes (identified by co-expression of pan-cytokeratin [CK+] and CD45+) and are distinct from conventional circulating tumor cells (CTCs), which lack immune phenotypes (CK+/CD45) [20,21,22,27,28].